Hopkinton Drug, Inc., Hopkinton, MA

Is Hopkinton Drug, Inc. registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Hopkinton Drug, Inc. hold a Massachusetts pharmacy license?

State board of pharmacy records for Massachusetts are not checked: the board’s website refused automated requests, and this index does not work around blocks. The Colorado State Board of Pharmacy also lists nonresident license OSP 6206 for Hopkinton Drug, Inc, Hopkinton, MA, status Expired, as of Nov 15, 2026. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054018556 for HOPKINTON DRUG INC, HOPKINTON, MA, status NOT RENEWED, as of Nov 13, 2026. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0002479 for HOPKINTON DRUG INC, HOPKINTON, MA, status INACTIVE, as of Nov 15, 2026. The Delaware Division of Professional Regulation also lists nonresident license A9-0001707 for Hopkinton Drug. Inc., HOPKINTON, MA, status Closed, as of Nov 10, 2026.

Has Hopkinton Drug, Inc. had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 untitled letter (Sep 16, 2021), 1 state referral letter (Mar 7, 2022) and 1 FMD-145 letter (Mar 7, 2022) for Hopkinton Drug, Inc. State board of pharmacy records for Massachusetts are not checked: the board’s website refused automated requests, and this index does not work around blocks. The Colorado State Board of Pharmacy’s license dataset also lists 2 actions: “CLS Letter of Admonition” dated Nov 16, 2022, case 2022-6603 on nonresident license OSP 6206 and “CLS Stipulation” dated Feb 2, 2015, case 2014-1600 on nonresident license OSP 6206. The Illinois Department of Financial and Professional Regulation’s license dataset also lists 2 actions: “Reprimand” dated Dec 5, 2018, case 2017005576 on nonresident license 054018556 and “Fine” dated Mar 17, 2016, case 2015001488 on nonresident license 054018556. The state referral and handoff letters above are FDA’s letters to the state, not board actions.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Hopkinton Drug, Inc.
Location
Hopkinton, MA
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
0
Latest action on that page
Mar 7, 2022
FDA Data Dashboard inspections
No matching site found
Form 483 text on this page
1 Form 483, 2 observations
State board records
Not checked

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Hopkinton Drug, Inc., a 503A facility, with 4 dated actions.

Document
Mar 7, 2022State referral letterState Referral Letter Issued 03/07/2022Not linked by FDA
Mar 7, 2022FMD-145 letterFMD-145 Letter Issued 03/07/2022Not linked by FDA
Sep 16, 2021Untitled letterUntitled Letter Issued 09/16/2021fda.gov
Nov 10, 2020Amended Form 483Amended 483 Issued 11/10/2020fda.gov

A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

No inspected site under this exact name and city was found in the FDA Data Dashboard on Nov 15, 2026, searching 12,593 US sites with a drug inspection ending Oct 1, 2008 to Oct 23, 2026. FDA may list the site under another legal name, so this is not a finding that it was never inspected.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 2 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Aug 25, 2020 to Nov 2, 2020: 2 observations

Firm on the cover
Hopkinton Drug, Inc., 52 Main St, Hopkinton, MA 01748-1 214
FEI number
3005543749
Establishment type on the cover
Producer of Non-Sterile Drug Products
FDA district office on the cover
One Montvale Avenue Stoneham, MA 02180
Matched to this page by
firm name, city and state on the cover; linked from actions page
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Non-microbial contamination was observed in your production area.

Specifically,

Thick white powder residues were observed on the ceiling intake vent over the <Redacted B4> hood (Asset# <Redacted B4> and on top of the <Redacted B4> hood within the firm's hazardous drug room <Redacted B4> The <Redacted B4> hood and room are utilized in the production of the following hazardous drug products. Cliolestyramine Pure Powder, Estrogen, Testosterone, Progesterone, Methylene Blue, and Disulfiram.

Large amounts of blue colored staining were observed on the inside of the door to the <Redacted B4> glasswasher within the firm's hazardous drug room. The glasswasher is utilized in the cleaning of glassware and equipment for the production of hazardous drug products.

Flaking pain rust spots and yellow colored staining were observed on the interior of the firm's <Redacted B4> (Asset <Redacted B4> balance which was located within the <Redacted B4> Asset# <Redacted B4> hood. The balance/hood are utilized in the weighing/production ielo' lowing non-hazardous drug products: creams/ointments and nasal sprays (Vasoactive intestinal peptide).

~j)

AMENDMENT 1 ...

Read the full 483 (PDF on fda.gov)

Observation 2

You produced hazardous drugs without providing adequate segregation, cleaning of work surfaces and cleaning of utensils to prevent cross-contamination.

Specifically,

You did not use a cleaner suitable for removing pharmaceutical residues and there is no evidence that the household cleaners used <Redacted B4> are capable of removing hazardous materials such as hormones, antibiotics and controlled substances.

A <Redacted B4> beaker within the fnm's clean glassware storage area was observed with an unknown opaque residue on the interior of the beaker.

Several containers of the following finished non-hazardous drug product were observed being stored within the firm's hazardous drug production room: Naltrexone 1.5mg lot# 07312020:97@1. In addition, review of the firm's <Redacted B4> for the following non­-hazardous drug products revealed that they had been processed within the firm's hazardous drug room: Naltrexone 3mg capsule lot# 07082020:33@7 and Naltrexone 3mg capsule lot# 08012020:33@1.

AMENDMENT 1

08012020:33@1.

State board of pharmacy records

State board of pharmacy records for Massachusetts are not checked: the board’s website refused automated requests, and this index does not work around blocks.

Nonresident licenses in other states

These boards list a nonresident license whose record names this pharmacy’s own name, city and state.

Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).

LicenseType as the board gives itName on the board recordLocationStatus
OSP 6206OSPHopkinton Drug, IncHopkinton, MAExpired

Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).

LicenseType as the board gives itName on the board recordLocationStatus
054018556LICENSED PHARMACYHOPKINTON DRUG INCHOPKINTON, MANOT RENEWED

Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).

LicenseType as the board gives itName on the board recordLocationStatus
PCN.0002479NONRESIDENT PHARMACYHOPKINTON DRUG INCHOPKINTON, MAINACTIVE

Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).

LicenseType as the board gives itName on the board recordLocationStatus
A9-0001707Non Resident PharmacyHopkinton Drug. Inc.HOPKINTON, MAClosed

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.